Breast cancer resistance protein (BCRP)‑containing circulating microvesicles contribute to chemoresistance in breast cancer

Chen,Yun; Wang,Linjun; Zhu,Yifei; Chen,Zhen; Qi,Xiaowei; Jin,Linfang; Jin,Jian; Hua,Dong; Ma,Xin

doi:10.3892/ol.2015.3806

Breast cancer resistance protein (BCRP)‑containing circulating microvesicles contribute to chemoresistance in breast cancer

Authors:
- Yun Chen
- Linjun Wang
- Yifei Zhu
- Zhen Chen
- Xiaowei Qi
- Linfang Jin
- Jian Jin
- Dong Hua
- Xin Ma
View Affiliations

Affiliations: School of Pharmaceutical Sciences, Jiangnan University, Wuxi, Jiangsu 214122, P.R. China, Department of Medical Oncology, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu 204062, P.R. China, Department of Pathology, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu 204062, P.R. China
Published online on: October 14, 2015 https://doi.org/10.3892/ol.2015.3806
Pages: 3742-3748

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

At present, one of the major problems of cancer therapy is drug resistance. Breast cancer resistance protein (BCRP), a marker of the multidrug‑resistant phenotype, affects drug absorption, distribution, metabolism, and excretion in normal tissues. Meanwhile, extracellular vesicles (EVs) have attracted increasing attention as a medium of cell‑to‑cell communication. However, the association between BCRP and circulating EVs remains unclear. The present study demonstrated that patients who did not respond or had progressive/stable disease following chemotherapy had markedly higher BCRP levels compared to those that did not receive chemotherapy. Moreover, BCRP was upregulated at the mRNA and protein levels in tumor‑derived circulating EVs from patients with a poor response to chemotherapy. Interestingly, the results also demonstrated that BCRP was co‑expressed with MUC1, which is frequently expressed in breast cancer and is exported via EVs, and both BCRP and MUC1 were up‑regulated after chemotherapy. In conclusion, the present study indicates that tumor‑derived circulating EVs that carry BCRP may serve as a predictive biomarker of the response to chemotherapy for breast cancer. In addition, the results provide a window for individualized treatment to overcome resistance to chemotherapeutic drugs.

View Figures

View References

1	Holohan C, Van Schaeybroeck S, Longley DB and Johnston PG: Cancer drug resistance: An evolving paradigm. Nat Rev Cancer. 13:714–726. 2013. View Article : Google Scholar : PubMed/NCBI
2	Cheung KL, Evans AJ and Robertson JF: The use of blood tumour markers in the monitoring of metastatic breast cancer unassessable for response to systemic therapy. Breast Cancer Res Treat. 67:273–278. 2001. View Article : Google Scholar : PubMed/NCBI
3	Weigel MT and Dowsett M: Current and emerging biomarkers in breast cancer: Prognosis and prediction. Endocr Relat Cancer. 17:R245–R262. 2010. View Article : Google Scholar : PubMed/NCBI
4	Raposo G and Stoorvogel W: Extracellular vesicles: Exosomes, microvesicles and friends. J Cell Biol. 200:373–383. 2013. View Article : Google Scholar : PubMed/NCBI
5	Holme PA, Solum NO, Brosstad F, Røger M and Abdelnoor M: Demonstration of platelet-derived microvesicles in blood from patients with activated coagulation and fibrinolysis using a filtration technique and western blotting. Thromb Haemost. 72:666–671. 1994.PubMed/NCBI
6	Hess C, Sadallah S, Hefti A, Landmann R and Schifferli JA: Ectosomes released by human neutrophils are specialized functional units. J. Immunol. 163:4564–4573. 1999.
7	Cocucci E, Racchetti G and Meldolesi J: Shedding microvesicles: Artefacts no more. Trends Cell Biol. 19:43–51. 2009. View Article : Google Scholar : PubMed/NCBI
8	György B, Szabó TG, Pásztói M, Pál Z, Misják P, Aradi B, László V, Pállinger E, Pap E, Kittel A, et al: Membrane vesicles, current state-of-the-art: Emerging role of extracellular vesicles. Cell Mol Life Sci. 68:2667–2688. 2011. View Article : Google Scholar : PubMed/NCBI
9	Harding CV, Heuser JE and Stahl PD: Exosomes: Looking back three decades and into the future. J Cell Biol. 200:367–371. 2013. View Article : Google Scholar : PubMed/NCBI
10	Ma X, Chen Z, Hua D, He D, Wang L, Zhang PJ, Cai Y, Gao C, Zhang X, et al: Essential role for TrpC5-containing extracellular vesicles in breast cancer with chemotherapeutic resistance. Proc Natl Acad Sci USA. 111:6389–6394. 2014. View Article : Google Scholar : PubMed/NCBI
11	Noguchi K, Katayama K and Sugimoto Y: Human ABC transporter ABCG2/BCRP expression in chemoresistance: Basic and clinical perspectives for molecular cancer therapeutics. Pharmgenomics Pers Med. 7:53–64. 2014.PubMed/NCBI
12	Brangi M, Litman T, Ciotti M, Nishiyama K, Kohlhagen G, Takimoto C, Robey R, Pommier Y, Fojo T and Bates SE: Camptothecin resistance: Role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res. 59:5938–5946. 1999.PubMed/NCBI
13	Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
14	Staubach S, Razawi H and Hanisch FG: Proteomics of MUC1-containing lipid rafts from plasma membranes and exosomes of human breast carcinoma cells MCF-7. Proteomics. 9:2820–2835. 2009. View Article : Google Scholar : PubMed/NCBI
15	Brouckaert O, Laenen A, Wildiers H, Floris G, Moerman P, Van Limbergen E, Vergote I, Billen J, Christiaens MR and Neven P: The prognostic role of preoperative and (early) postoperatively change in CA15.3 serum levels in a single hospital cohort of primary operable breast cancers. Breast. 22:254–262. 2013. View Article : Google Scholar : PubMed/NCBI
16	Gion M, Mione R, Leon AE and Dittadi R: Comparison of the diagnostic accuracy of CA27.29 and CA15.3 in primary breast cancer. Clin Chem. 45:630–637. 1999.PubMed/NCBI
17	Wang X, Yang Q, Guo L, et al: Flotillin-2 is associated with breast cancer progression and poor survival outcomes. J Transl Med. 11:1902013. View Article : Google Scholar : PubMed/NCBI
18	Burger H, Foekens JA, Look MP, van Gelder Meijer ME, Klijn JG, Wiemer EA, Stoter G and Nooter K: RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2 and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. Clin Cancer Res. 9:827–836. 2003.PubMed/NCBI
19	Marić P, Ozretić P, Levanat S, Oresković S, Antunac K and Beketić-Oresković: Tumor markers in breast cancer - evaluation of their clinical usefulness. Coll Antropol. 35:241–247. 2011.